Menu
X

Tags Archives: CAR-T Cell Therapy


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
11 months ago CAR-T

Exploring Tumor Vitality: Chinese CAR-T Therapy Grants Patients Complete Remission

Exploring Tumor Vitality: Chinese CAR-T Therapy Grants Patients Complete Remission
CancerSurvivor
“Is it true? It’s so unbelievable!” said Chen, the “fortunate one.”
 
On June 22, 2021, the approval of China’s first CAR-T cell therapy product, Yescarta, marked a significant milestone in medicine. Behind this milestone lies the story of a patient named Chen, diagnosed with diffuse large B-cell lymphoma, which not only brought confidence to patients but also injected fresh belief into medical professionals.
 
Chen was diagnosed with diffuse large B-cell lymphoma in July 2019, underwent primary treatment, only to unfortunately relapse. Due to the insufficient efficacy of secondary treatment and considering the TP53 mutation, conventional treatment plans were inadequate. However, the approval of Yescarta on June 22, 2021, brought a glimmer of hope for patients. Under the meticulous planning of the expert team in the Hematology Department of Ruijin Hospital, Chen successfully underwent CAR-T cell infusion therapy on August 2.
One year after the evaluation of the treatment’s effectiveness, Chen’s condition still maintains complete remission. This achievement has brought immense hope and joy to patients with diffuse large B-cell lymphoma, strengthening the belief in the potential of CAR-T therapy among medical practitioners.
 
“This is not only good news for patients but also an encouragement and boost to us, clinical doctors in the field of hematology,” stated Professor Xu Pengpeng.
This case represents not only a medical breakthrough but also serves as an inspiration for individuals battling diffuse large B-cell lymphoma. The success of CAR-T therapy reveals new possibilities, offering a new pathway to break the limitations of the “mere six-month survival period” in cancer treatment. May more patients benefit from this breakthrough, offering hope for healing and long-term remission.
 
#CARTtherapy #TumorVitality #CancerTreatment #NewMedicalTechnologies #MedicalAdvancement #Bloodcancer #cancersuvivor #lymphoma


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
11 months ago CAR-T

Two Years of Complete Remission(Lymphoma), CAR-T therapy has given her a new lease on life.

“Two Years of Complete Remission, CAR-T therapy has given her a new lease on life.  She Thought the Journey Was Over”

 

Yun is a 78-year-old patient who achieved a continuous complete remission for two and a half years despite relapsed/refractory diffuse large B-cell lymphoma. Diagnosed in 2019, after enduring six rounds of chemotherapy, she initially achieved complete remission as confirmed by her healthcare team. Unfortunately, the period of remission was short-lived as Yun soon experienced disease relapse, and subsequent second-line treatments failed to yield positive results.

“I vividly remember when Director Wang Li encouraged me, mentioning an advanced method called Car-T, but it was quite expensive. I was hesitant, but I discussed it with my son when I got home. When my son and daughter-in-law heard about it, they insisted on treatment. My son said, ‘Mom, you’re the only mother I have in this world. As long as you’re here, our home is complete. Money can be earned again, and if the treatment isn’t successful, at least we won’t have regrets.’ I was deeply moved. At my age, I’ve already shown strength through previous treatments. I believe that wherever my health takes me is where I belong. Everyone’s support gave me a reason to stay strong again.”

In 2021, CAR-T cell therapy was approved and launched in China, and Yun underwent this treatment at Ruijin Hospital.

Dr. Wang Li, Director of Hematology at Ruijin Hospital, explained, “CAR-T cell therapy provides new treatment options for a wide range of cancer patients.”

“Before planning Yun’s CAR-T cell therapy, lymphoma experts, considering her current tumor status and medical history, anticipated potential adverse reactions during the treatment process and discussed handling protocols. Yun’s entire journey with CAR-T cell therapy was challenging. The medical team meticulously coordinated their efforts, successfully addressing adverse reactions after CAR-T treatment, ultimately averting potential risks.”

Despite lying in her hospital bed, Yun deeply appreciates the relentless dedication of her medical caregivers. “Sometimes, directors come to see me after 10 p.m., telling me they worked late but had to check on me; some arrive by my bedside as early as 7 a.m., concerned about my well-being. I continuously remind myself that I must strive, persist, and live up to the efforts made by doctors and my entire family,” said the 78-year-old Yun . “I made it through.”

#CARTCellSuccess #CancerWarrior #CompleteRemissionChronicles  #FamilySupportMatters #CAR-TBreakthrough #InspiringHealthJourney #MedicalMiracles #NeverTooLateToFight #Cancerfight #Bloodcancer

#lymphoma


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
11 months ago CAR-T

Breakthrough Advances in CAR-T Cell Therapy Combined with TKI for Malignant Hematologic System Tumors

Breakthrough Advances in CAR-T Cell Therapy Combined with TKI for Malignant Hematologic System Tumors
At this year’s ASH conference, Professor Huang He, the director of the First Affiliated Hospital of Zhejiang University School of Medicine, presented a significant study on CAR-T cell therapy for B-ALL, marking a groundbreaking stride in the treatment of malignant hematologic system tumors.
 
This study, targeting newly diagnosed adult Ph-positive acute lymphoblastic leukemia, investigated the combined treatment of dasatinib and CAR-T cell therapy as a frontline therapy for initial patients. The integration of CAR-T cell therapy with tyrosine kinase inhibitors (TKI) aimed to enhance treatment effectiveness.
 
The study revealed promising outcomes: among 18 patients, the complete molecular remission rate after CD19 CAR-T cell therapy reached 72.2%. Among these patients, subsequent treatment with CD22 CAR-T cells achieved a complete molecular remission rate of 76.9%. At a median follow-up of 13.5 months post CAR-T cell therapy, 16 patients maintained complete hematological remission, while 14 patients sustained complete molecular remission without undergoing allogeneic transplantation. Notably, no CRS (cytokine release syndrome) ≥ Grade 3 or ICANS (immune effector cell-associated neurotoxicity syndrome) occurred during CAR-T cell therapy.
Professor Huang He’s team’s groundbreaking research presented at the ASH conference signifies a leap forward in the treatment of blood-related cancers, signaling a more efficient and accessible era. These findings instill hope for refining treatment strategies and potentially making a significant impact in the field of hematologic oncology.
Beyond the groundbreaking progress in CAR-T cell therapy combined with TKI, the team showcased seven oral presentations and 26 poster exhibitions. These studies encompassed fundamental research on blood disorders, leukemia pathogenesis, acute lymphoblastic leukemia, acute myeloid leukemia, lymphoma, myeloma, hematopoietic stem cell transplantation, and cellular immunotherapy, all crucial for enhancing clinical practices.
 
We eagerly anticipate further groundbreaking strides by Chinese research teams in cancer treatment studies, anticipating the transformative impact of these research findings in the future.
 
 
#ASHAnnualMeeting #HematologyResearch #CARTCellTherapy #StemCellTransplantation #BloodCancer #ClinicalInnovation #OncologyAdvancements #Cancertherapy #MedicalResearch #ASH #CART #CARTTherapy #CARTCell #TKI #tyrosinekinaseinhibitors


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
11 months ago CAR-T

Chinese Research: Hopes of CAR-T in Second-Line Treatment of LBCL(Lymphoma)

Diffuse Large B-cell Lymphoma (LBCL)is a heterogeneous malignant tumor of the blood system, with approximately 40% of LBCL patients experiencing relapse or developing resistance after first-line treatment, progressing to relapsed/refractory large B-cell lymphoma (R/R LBCL). In recent years, chimeric antigen receptor T-cell therapy targeting CD19 (CAR-T) has made significant breakthroughs in treating relapsed or refractory B-cell non-Hodgkin lymphoma.
At the 65th American Society of Hematology (ASH) Annual Meeting held from December 9th to 12th this year in the Eastern United States, important real-world evidence of CAR-T cell therapy as a second-line standard treatment for R/R LBCL was presented in the form of a poster (ASH Abstract #4876), providing crucial evidence-based medicine for the clinical application of CAR-T.
 
CAR-T Cell Therapy as Second-Line Treatment for R/R LBCL: Real-World
Evidence Among 110 patients receiving CAR-T infusion, the overall response rate (ORR) was 82.7%, and the complete response (CR) rate was 61.8%. Median progression-free survival (PFS) and overall survival (OS) were not reached. Estimated 6-month PFS and OS rates were 64.1% (95% CI, 52.8%-73.4%) and 84.4% (95% CI, 73.8%-90.9%), respectively.
The advent of CAR-T cell therapy has brought hope of cure for R/R LBCL patients. Based on its critical research and outstanding real-world application data, CAR-T cell therapy has gained recommendations from authoritative guidelines at home and abroad, and has become a crucial choice for second-line treatment in R/R LBCL patients.
 
#CARTCellTherapy #CancerTreatment #ScienceInnovation #GeneticMedicine #TumorTreatment #HealthcareTech #MedicalScience #CancerAwareness #PatientCare #FutureOfMedicine #CART #LBCL #Lymphoma #bloodcancer 

11 months ago CAR-T

Unveiling Hope: Chinese CAR-T Cell Therapy Illuminating New Paths in Liver Cancer Treatment!

2020, over 19.3 million people were diagnosed with cancer worldwide, leading to almost 10 million fatalities. In China alone, the number of new cancer patients reached a staggering 4.57 million, accounting for 23.7% globally. Liver cancer, among the most prevalent malignant tumors in China, witnessed 410,000 new cases and 380,000 deaths, making up 45.3% and 47.1% of the global total, respectively [1]. However, since the 21st century began, significant strides have been made in liver cancer treatments, particularly in medication and localized therapies. Surgical procedures are no longer the sole option for long-term survival among liver cancer patients.

Immunotherapy has emerged as one of the most promising techniques for treating liver cancer, especially with advancements in tumor molecular biology. In 2013, “Science” magazine categorized immunotherapy as the fourth major cancer treatment, following surgery, chemotherapy, and radiation therapy, with cell therapy becoming a focal point of basic and clinical research in recent years.

In May 2020, Professor Zhai Bo’s team from Shanghai Jiao Tong University School of Medicine’s Renji Hospital, in collaboration with Shanghai Sci-Tech Biotechnology’s team led by Li Zonghai, published groundbreaking preliminary clinical research data on CAR-T cell therapy targeting the GPC3 gene for hepatocellular carcinoma in the “Clinical Cancer Research” journal. This breakthrough study brought unprecedented hope for CAR-T cell therapy in liver cancer treatment.

Even more inspiring, their publication in the “Cancer Communications” journal showcased follow-up results of two late-stage liver cancer patients who achieved long-term tumor-free survival after receiving CAR-T cell combined with local therapy [2]. These findings shed new light on the treatment prospects for liver cancer patients.

However, despite the potential therapeutic effects of liver cancer CAR-T cell therapy, it faces challenges and obstacles. Liver cancer’s heterogeneity, tumor microenvironment, and the safety of cell therapy remain crucial issues to address.

Presently, revolutionary changes are underway in the treatment models and concepts for liver cancer. However, integrating CAR-T cell therapy into actual liver cancer treatment requires further scientific exploration and clinical research. Researchers emphasize that only through comprehensive utilization of CAR-T cells in conjunction with other treatment modalities can its therapeutic potential be fully realized.

Professor Zhai Bo’s team is currently conducting various fundamental and clinical studies aimed at exploring additional possibilities for CAR-T cell therapy in solid tumors. These studies include phase I clinical research on EpCAM CAR-T cell combined with ablative therapy for gastrointestinal tumors, phase II clinical research on Claudin18.2 CAR-T cell therapy for gastrointestinal tumors, studies on the mechanism and prevention of OTOT toxicity, among others. These endeavors will provide more experimental data and support for the application of CAR-T cells in the treatment of solid tumors.

In conclusion, liver cancer CAR-T cell therapy signifies a significant breakthrough in the field of liver cancer treatment, offering new hope for patients. Despite the challenges to overcome, the outlook for this therapy is promising and holds the potential to bring a blessing to more patients in the future.

[References]

Zhaibo, Lizonghai etc.

“Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase 1 Trials.” 《Clinical Cancer Research》, 2020.

“Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy.” 《Cancer Communications》, 2023.

 

#HealthTech#CancerResearch #Immunotherapy #CARTcell #LiverCancer #MedicalBreakthrough #ClinicalTrials #ScienceNews #HealthcareInnovation #ResearchBreakthrough #MedicalScience #CancerTherapy #CancerAwareness #InnovativeMedicine #ImmunotherapyTreatment #ScienceUpdates #HealthcareTechnology #BiomedicalResearch #ClinicalInnovation #CancerTreatment #MedicalAdvancements #ImmunologyResearch #HealthcareIndustry #ProfessionalHealthcare

11 months ago CAR-T

The Emergence of Fifth Generation CAR-T: A Boon for Late-Stage Cancer Patients or a Major Breakthrough in Solid Tumor Treatment?

The fifth-generation CAR-T is designed as a universal type of CAR-T. Is this risk-free CAR-T capable of achieving significant breakthroughs in solid tumor treatment, or is it effectively reducing costs to enable scalable production and treatment?

After nearly three decades of development, CAR (Chimeric Antigen Receptor) technology has undergone continuous innovation. Currently, CAR has evolved to its fifth generation. Its aim is to enhance the safety of treatments by reducing toxicity and non-specific antigen recognition. This is achieved by stimulating proliferation, activation, and the generation of memory phenotypes within CAR-T cells to improve efficiency and provide immune regulation for the optimal function of CAR-T cells.

 

Generation CAR-T

Generation CAR-T

The Evolution of Different Generations of CAR-T

First Generation CAR:

The first-generation CAR comprises an extracellular single-chain variable fragment (scFv) as the antigen recognition binding domain and an intracellular CD3ζ as the cellular activation signaling domain. Despite initiating cytotoxic anti-tumor responses within transplanted T cells, first-generation CAR-T cells exhibit lower levels of cytotoxicity and proliferation due to the CAR structure lacking co-stimulatory domains, which results in inadequate interleukin (IL)-2 production.

 

Second Generation CAR:

Building upon the CD3ζ signal transduction domain, the second-generation CAR includes an additional co-stimulatory signaling domain that activates T cells, significantly enhancing T cell proliferation and survival. For instance, CD28 can deliver robust activation signals, enabling T cells to achieve high levels of cytotoxic activity in a shorter duration, while 4-1BB provides prolonged activation signals, sustaining T cell-mediated killing of tumor cells. However, limitations arise in second-generation CAR-T cells utilizing retroviruses as viral vectors, restricting the length of transgene fragments they can carry. As a result, it becomes necessary to choose between incorporating CD28 and 4-1BB into T lymphocytes.

 

Third Generation CAR:

Third-generation CAR-T cells utilize larger DNA-carrying lentiviruses as viral vectors, allowing simultaneous incorporation of DNA fragments for both CD28 and 4-1BB into T cells. Consequently, the third-generation CAR structure encompasses two co-stimulatory domains, theoretically addressing the need for higher activation intensity and sustained survival of CAR-T cells. However, the safety concerns associated with prolonged and high-level persistence of CAR-T cells, including potential attacks on the host’s immune system, remain unresolved despite these advancements.

 

Fourth Generation CAR:

The design concept behind the fourth-generation CAR revolves around the precise treatment of cancerous diseases. For instance, solid tumors generate a microenvironment (TME) during their chronic progression, preventing CAR-T cells from penetrating the tumor interior. As a result, CAR-T therapy demonstrates limited efficacy in treating solid tumors. TRUCK CAR-T involves incorporating cytokines (such as IL-12) or chemokines into the CAR structure. This facilitates increased infiltration of T cells into tumor tissues while recruiting other immune cells within the body to eliminate tumor cells. In some studies, a suicide gene or certain drug-sensitive genes are attached to the CAR structure to ensure the clearance of CAR-T cells from the body post-treatment, preventing inadvertent harm to normal cells and enhancing the safety and controllability of CAR-T therapy.

 

Fifth Generation CAR:

The fifth-generation CAR-T, known as universal CAR-T, achieves T-cell receptor α (TCR-α) and β (TCR-β) chain deletion by knocking out the TRAC gene. This implies the removal of the T-cell receptor (TCR) from the surface of T cells, thereby avoiding the occurrence of graft-versus-host disease (GVHD) in transplantation reactions.

Since the FDA’s approval of the CD19 CAR-T product, Novartis’s Kymriah, in 2017, CAR-T cell therapy has entered a stage of rapid development. However, the currently approved and marketed products are all second-generation CAR-T therapies. There is still a long way to go for CAR-T to become widespread in the market.

Safety concerns constitute the primary challenge for CAR-T, such as off-target effects, cytokine release syndrome (CRS), and neurotoxicity (NTX). Currently available CAR-T products primarily focus on treating hematologic malignancies, with no major breakthroughs achieved yet in treating solid tumors.

In 2021, China’s NMPA approved three CAR-T products for marketing: FOSUNKITE’s Axicabtagene Ciloleucel injection, JW Therapeutics’s Relmacabtagene Autoleucel Injection, and the recently approved JUVENTAS’s Inaticabtagene Autoleucel Injection, all targeting CD19. Additionally, earlier this year, IASO Bio obtained approval for Equecabtagene Autoleucel Injection, targeting BCMA. While CAR-T targeting CD19 has shown effectiveness, its scope remains limited to B-cell-related hematologic malignancies. BCMA-targeted CAR-T is restricted to treating multiple myeloma. To address solid tumor treatment, the development of more specific and potent targets is necessary.

Among the recently released domestically developed JUVENTAS’s Inaticabtagene Autoleucel Injection, its competitive advantage lies in its price, which has decreased to below one million RMB(Approximately $140,000 US).

With the continuous advancement of molecular biology technologies, more breakthroughs are expected in CAR molecule design. This progression anticipates the development of safer and more efficient universal CAR-T therapies in the future, benefiting a broader spectrum of cancer patients.

“If you’d like to inquire about the latest cancer-fighting technologies and treatments, you can contact us.”

whatsapp:+8613717959070

#CARTCellTherapy #CancerTreatment #ScienceInnovation #GeneticMedicine #TumorTreatment #HealthcareTech #MedicalScience #CancerAwareness #PatientCare #FutureOfMedicine

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.